Genor Biopharma Co., Ltd.
24
1
1
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 24 trials
100.0%
+13.5% vs industry average
17%
4 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (24)
A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors
Role: lead
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
Role: lead
A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL.
Role: lead
A Study of [14C]GB491 in Male Healthy Subjects
Role: lead
A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Role: lead
A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor
Role: lead
A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer
Role: lead
Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma
Role: lead
Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®
Role: lead
Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)
Role: lead
Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)
Role: lead
Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib
Role: lead
Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection
Role: lead
A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive
Role: lead
Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)
Role: lead
Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer
Role: lead
Clinical Trial of Comparative Study of GB221 Pharmacokinetics
Role: lead
Phase I Clinical Study of GB222 to Evaluate the Safety, Tolerability and PK Profiles.
Role: lead
A Study to Evaluate the Safety and Tolerability of Multiple Doses of Gerilimzumab in Rheumatoid Arthritis Patients
Role: lead
Phase Ⅰ Clinical Trial of Gerilimzumab Injection in Healthy Subjects
Role: lead